NCLT: Suspended Directors Who are Prospective Resolution Applicants Cann’t Access Valuation Reports  ||  Supreme Court Clarifies Test For Granting Bail to Accused Added at Trial under Section 319 CrPC  ||  SC: Fresh Notification For Vijayawada ACB Police Station not Required After AP Bifurcation  ||  SC: Studying in a Government Institute Does Not Create an Automatic Right to a Government Job  ||  NCLT Mumbai: CIRP Claims Cannot Invoke the 12-Year Limitation Period For Enforcing Mortgage Rights  ||  NCLAT: Misnaming Guarantor as 'Director' in SARFAESI Notice Doesn't Void Guarantee Invocation  ||  Jharkhand HC: Mere Breach of Compromise Terms by an Accused Does Not Justify Bail Cancellation  ||  Cal HC: Banks Cannot Freeze a Company's Accounts Solely Due To ROC Labeling a 'Management Dispute'  ||  Rajasthan HC: Father’s Rape of His Daughter Transcends Ordinary Crime; Victim’s Testimony Suffices  ||  Delhi HC: Judge Who Reserved Judgment Must Deliver Verdict Despite Transfer; Successor Can't Rehear    

Commerce Minister releases study report on Indian pharma exports to China- (Press Information Bureau) (18 Jun 2018)

MANU/PIBU/0962/2018

Commercial

For India to make a strong pitch for pharma exports to China, the Department of Commerce in coordination with Embassy of India at Beijing commissioned a study on "Enhancing Indian Exports of Pharmaceutical products to China" under the Market Access Initiative Scheme (MAI) to have a proper understanding of Chinese market and to help the Indian pharma industry to evolve appropriate and focused strategy for entry of the Indian generic drugs.

The study examines the health care market, pharmaceutical market the distribution system, procurement and bidding process and the regulatory landscape in China. The study also gives recommendations on how to access the Chinese market.

China' s health-care sector continues to grow rapidly with spending projected to grow from $ 357 billion in 2011 to $ 1 trillion in 2020. From pharmaceuticals to medical products to consumer health, China remains among the world's most attractive markets, and by far the fastest-growing of all the large emerging ones.

The study has been done by IMS Health team which worked with PHARMEXCIL and Industry stakeholders.

Tags : CHINA   PHARMA   EXPORT  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved